Bausch Health Announces Litigation Updates With Norwich Pharmaceuticals; Bausch Health And Norwich Have Filed Petitions For Panel Rehearing Or Rehearing En Banc
Portfolio Pulse from Benzinga Newsdesk
Bausch Health (BHC) and Norwich Pharmaceuticals have filed for panel rehearing or rehearing en banc regarding their ongoing litigation. This move could delay the FDA's approval of Norwich's ANDA for up to 30 months or until a district court decision against Bausch Health.
May 14, 2024 | 8:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
The litigation and subsequent filing for a panel rehearing or rehearing en banc by Bausch Health and Norwich Pharmaceuticals could delay FDA approval of Norwich's ANDA, impacting Bausch Health's competitive position and potentially its financial outlook.
The delay in FDA approval for Norwich's ANDA due to the litigation with Bausch Health could negatively impact Bausch Health's market position by preventing potential competition from entering the market. This could have a short-term negative impact on BHC's stock as investors may view the ongoing litigation and potential delay as risks to Bausch Health's future revenue and market share.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100